|
1. Hauser SL, Cree BA. Treatment of multiple sclerosis: a review. Am J Med 2020;133:1380-90. e2. doi: 10.1016/j.amjmed.2020.05.049 . 2. Warren S. Epidemiology of multiple sclerosis. Neuroepidemiology: CRC Press; 2019. p. 239-64. doi:10.1016/j.ncl.2016.06.016 . 3. Magyari M, Sorensen PS. The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis. Curr Opin Neurol 2019;32:320-6 .doi: 10.1097/WCO.0000000000000695 . 4. Azami M, YektaKooshali MH, Shohani M, Khorshidi A, Mahmudi L. Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis. PLoS One 2019;14:e0214738 .doi: 10.1371/journal.pone.0214738. 5. Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis. Neuroepidemiology 2015;44:232-44 .doi: 10.1159/000431042. 6. Elhami S-R, Mohammad K, Sahraian MA, Eftekhar H. A 20-year incidence trend (1989–2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study. Neuroepidemiology 2011;36:141-7 .doi: 10.1159/000324708. 7. Bagherieh S, Mirmosayyeb O, Vaheb S, Afshari-Safavi A, Barzegar M, Ashtari F, et al. Prevalence and Incidence of Multiple Sclerosis in Isfahan Province, Iran: A 25-Year Population-Based Study. Mult Scler Relat Disord 2023;71:104310 .doi: 10.1016/j.msard.2022.104310. 8. Saadatnia M, Etemadifar M, Maghzi AH. Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol 2007;79:357-75 .doi: 10.1016/S0074-7742(07)79016-5. 9. Alfredsson L, Olsson T. Lifestyle and environmental factors in multiple sclerosis. Cold Spring Harb Perspect Med 2019;9. doi: 10.1101/cshperspect.a028944. 10. Land WG. Role of DAMPs and cell death in autoimmune diseases: the example of multiple sclerosis. Genes Immun 2023;24:57-70 .doi: 10.1038/s41435-023-00198-8. 11. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA 2021;325:765-79 .doi: 1001/jama.2020.26858. 12. Baumstarck K, Boyer L, Boucekine M, Michel P, Pelletier J, Auquier P. Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge. Mult Scler Int 2013; 2013 .doi: 10.1155/2013/524894. 13. Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry—novel perspectives on brain disorders. Nat Rev Neurol 2019;15:317-28 .doi: 10.1038/s41582-019-0174-4. 14. Matute-Blanch C, Montalban X, Comabella M. Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. Handb Clin Neurol 2018;146:67-84 . doi: 10.1016/B978-0-12-804279-3.00005-8. 15. Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez MÁ, Meca-Lallana V, Ramió-Torrentà L. Cognitive dysfunctions and assessments in multiple sclerosis. Front Neurol 2019;10:581 .doi: 10.3389/fneur.2019.00581. 16. Möller A, Wiedemann G, Rohde U, Backmund H, Sonntag A. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand 1994;89:117-21. doi: 10.1111/j.1600-0447.1994.tb01497.x. 17. Schoonheim MM, Hulst HE, Landi D, Ciccarelli O, Roosendaal SD, Sanz-Arigita EJ, et al. Gender-related differences in functional connectivity in multiple sclerosis. Mult Scler 2012;18:164-73. doi: 10.1177/1352458511422245. 18. Drulovic J, Kisic-Tepavcevic D, Pekmezovic T. Epidemiology, diagnosis and management of sexual dysfunction in multiple sclerosis. Acta Neurol Belg 2020;120:791-7 .doi: 10.1007/s13760-020-01323-4. 19. Alsaadi T, El Hammasi K, Shahrour TM, Shakra M, Turkawi L, Mudhafar A, et al. Prevalence of depression and anxiety among patients with multiple sclerosis attending the MS clinic at Sheikh Khalifa Medical City, UAE: Cross-Sectional Study. Mult Scler Int 2015; 2015:487159. doi: 10.1155/2015/487159. 20. Hsu W-Y, Cheng C-H, Zanto TP, Gazzaley A, Bove RM. Effects of transcranial direct current stimulation on cognition, mood, pain, and fatigue in multiple sclerosis: a systematic review and meta-analysis. Front Neurol 2021;12:626113.doi: 10.3389/fneur.2021.626113 . 21. Leshno A, Sagiv O, Aloni R, Skaat A, Achiron A, Huna-Baron R, et al. Cognitive Performance of Patients With Multiple Sclerosis and Optic Neuritis at Presentation. J Neuroophthalmol 2022;42:e8-e13 . doi: 10.1097/WNO.0000000000001245. 22. Carotenuto A, Costabile T, Pontillo G, Moccia M, Falco F, Petracca M, et al. Cognitive trajectories in multiple sclerosis: a long-term follow-up study. Neurol Sci 2022;43:1215-22. doi: 10.1007/s10072-021-05356-2 . 23. Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 2017;23:721-33. doi: 10.1177/1352458517690821. 24. Beier M, Hughes AJ, Williams MW, Gromisch ES. Brief and cost-effective tool for assessing verbal learning in multiple sclerosis: Comparison of the Rey Auditory Verbal Learning Test (RAVLT) to the California Verbal Learning Test–II (CVLT-II). J Neurol Sci 2019;400:104-9. doi: 10.1016/j.jns.2019.03.016. 25. Hassanshahi E, Asadollahi Z, Azin H, Hassanshahi J, Hassanshahi A, Azin M. Cognitive function in multiple sclerosis patients based on age, gender, and education level. Acta Medica Iranica 2020:500-7. doi: 10.18502/acta.v58i10.4912. 26. Odintsova TA, Kopchak OO. Sleep disorders in relapsing-remitting multiple sclerosis patients. Wiad Lek 2021;74:257-62.doi: 10.1177/20552173221144229 . 27. Boeschoten RE, Braamse AM, Beekman AT, Cuijpers P, van Oppen P, Dekker J, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci 2017;372:331-41. doi: 10.1016/j.jns.2016.11.067. 28. Ruano L, Portaccio E, Goretti B, Niccolai C, Severo M, Patti F, et al. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler 2017;23:1258-67. doi: 10.1177/1352458516674367. 29. Planche V, Gibelin M, Cregut D, Pereira B, Clavelou P. Cognitive impairment in a population‐based study of patients with multiple sclerosis: differences between late relapsing− remitting, secondary progressive and primary progressive multiple sclerosis. Eur J Neurol 2016;23:282-9. doi: 10.1111/ene.12715.
|
